The Food and Drug Administration on Friday granted accelerated approval to Leqembi, a new antibody treatment for Alzheimer's disease, opening a second U.S. pathway for a drug designed to remove amyloid from the brain while leaving important questions about clinical benefit, safety monitoring and Medicare access unresolved.

Leqembi, or lecanemab-irmb, is indicated for Alzheimer's disease and should be initiated in patients with mild cognitive impairment or mild dementia, the stage studied in clinical trials. The FDA's Drug Trials Snapshot identifies January 6 as the original approval date and describes an intravenous infusion given every two weeks. The accelerated approval rests on reduction in amyloid-beta plaques, a surrogate endpoint considered reasonably likely to predict clinical benefit.

Approval rests on amyloid reduction while a larger trial supports the next step

Eisai and Biogen, which are developing and commercializing the treatment, said in their January 6 approval announcement that the decision was based on Phase 2 data showing a reduction in amyloid plaque. The recommended dose is 10 milligrams per kilogram every two weeks after confirming amyloid pathology.

At the same time, a much larger Phase 3 trial has already produced clinical results. The Clarity AD study, published in the New England Journal of Medicine in November, enrolled 1,795 people with early Alzheimer's disease. At 18 months, the mean change on the Clinical Dementia Rating-Sum of Boxes was 1.21 points in the lecanemab group and 1.66 in the placebo group, a difference of 0.45 points favoring treatment. The study also found greater amyloid reduction and differences favoring lecanemab on several secondary cognitive and functional measures.

The distinction between the regulatory basis for Friday's action and the Phase 3 evidence matters. Accelerated approval allows a drug for a serious condition to reach the market based on a surrogate measure while confirmatory evidence is assessed. Eisai filed a supplemental application for traditional approval on the same day, using Clarity AD as the confirmatory study. FDA still must review that filing before deciding whether the clinical evidence supports conversion to traditional approval.

The benefit is measurable, but so are treatment risks

Leqembi is not a cure and does not restore cognition already lost to Alzheimer's disease. Its potential value lies in slowing progression during early disease. The Phase 3 results showed statistically significant separation from placebo, but the treatment requires repeated infusions and imaging surveillance and carries risks associated with amyloid-removing antibodies.

In the Clarity AD trial, amyloid-related imaging abnormalities with edema or effusions, known as ARIA-E, occurred in 12.6 percent of lecanemab recipients. Infusion-related reactions occurred in 26.4 percent. The companies' Biogen approval release also emphasizes monitoring for ARIA and recommends MRI examinations before treatment and before selected infusions during the early months of therapy.

The FDA snapshot says the evidence supporting approval involved 1,795 patients at 253 sites in 13 countries, with 53 percent enrolled in the United States. The agency's prescribing framework limits the studied population to people with mild cognitive impairment or mild dementia and confirmed amyloid pathology, meaning diagnosis and treatment will require more than a routine prescription. Patients may need amyloid testing, specialist evaluation, infusion capacity and serial MRI monitoring.

Medicare coverage could determine how broadly the treatment is used

Regulatory approval does not automatically translate into broad access for a disease concentrated among older Americans. The Centers for Medicare & Medicaid Services said in a January 6 statement that it would continue to review emerging data and was committed to timely access to treatments that improve clinically meaningful outcomes. But CMS's existing national coverage policy for anti-amyloid antibodies limits coverage of products receiving accelerated approval to people enrolled in qualifying clinical trials.

That policy, established amid controversy over the earlier Alzheimer's drug Aduhelm, means the pathway to widespread Medicare reimbursement for Leqembi may depend on whether FDA ultimately grants traditional approval. Eisai's own approval announcement acknowledges that Medicare patients do not currently have broad access under the accelerated-approval status.

The access issue is especially consequential because Alzheimer's disease affects millions of Americans and treatment is likely to require ongoing infusions, imaging and specialist care in addition to the drug itself. An Associated Press report on Friday said Eisai set the annual list price at $26,500, before accounting for the additional medical services needed to identify eligible patients and monitor treatment.

A new Alzheimer's treatment enters a contested field

Leqembi arrives after years of failed Alzheimer's trials and a contentious debate over whether removing amyloid meaningfully changes the course of disease. The accelerated approval of Aduhelm in 2021 drew criticism because of uncertainty over clinical benefit and disagreement within FDA's advisory process. Leqembi's development differs in an important respect: the larger confirmatory trial has already been completed and reported before this accelerated approval.

That does not settle the scientific or clinical debate. The observed slowing in Clarity AD must be weighed against safety risks, treatment burden, cost and the question of how patients and families value a modest difference in decline over 18 months. The Phase 3 investigators themselves concluded that longer trials are needed to understand efficacy and safety over time.

For clinicians, the immediate task is therefore more complicated than deciding whether an approved drug exists. Appropriate patients must be identified early, amyloid pathology confirmed, MRI risk assessed and the potential benefit discussed alongside brain swelling, bleeding and infusion reactions. For Medicare, the decision is whether and when the evidence justifies broader reimbursement.

Friday's approval is nonetheless a major development in a field with few disease-modifying options. Leqembi is now legally available under the accelerated pathway, and a traditional-approval application is already before FDA. The next phase will test whether the clinical signal seen in Clarity AD is strong enough to support broader regulatory and insurance access—and whether the health system can safely deliver a treatment that demands far more infrastructure than an ordinary prescription medicine.